Insight on mutation-induced resistance to anaplastic lymphoma kinase inhibitor ceritinib from molecular dynamics simulations

Biopolymers ◽  
2019 ◽  
Vol 110 (2) ◽  
pp. e23257 ◽  
Author(s):  
Mu-Yang He ◽  
Wei-Kang Li ◽  
Jens Meiler ◽  
Qing-Chuan Zheng ◽  
Hong-Xing Zhang
Keyword(s):  
Molecular Dynamics ◽  
Molecular Dynamics Simulations ◽  
Induced Resistance ◽  
Anaplastic Lymphoma Kinase ◽  
Kinase Inhibitor ◽  
Anaplastic Lymphoma Kinase Inhibitor ◽  
Anaplastic Lymphoma ◽  
Dynamics Simulations

scholarly journals Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma Cells

2019 ◽  
Vol 9 ◽  
Author(s):  
Muhammad Wasi Alam ◽  
Marcus Borenäs ◽  
Dan E. Lind ◽  
Diana Cervantes-Madrid ◽  
Ganesh Umapathy ◽  
...  
Keyword(s):  
Anaplastic Lymphoma Kinase ◽  
Kinase Inhibitor ◽  
Neuroblastoma Cells ◽  
Anaplastic Lymphoma Kinase Inhibitor ◽  
Anaplastic Lymphoma ◽  
Alk Positive

scholarly journals EML4-ALK, a potential therapeutic target that responds to alectinib in ovarian cancer

2020 ◽  
Vol 50 (12) ◽  
pp. 1470-1474
Author(s):  
Beina Hui ◽  
Jingping Zhang ◽  
Xiaobo Shi ◽  
Fangfang Xing ◽  
Yang W Shao ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Anaplastic Lymphoma Kinase ◽  
Kinase Inhibitor ◽  
Fusion Gene ◽  
Ovarian Cancer Cells ◽  
High Grade ◽  
Serous Ovarian Cancer ◽  
Kinase Gene ◽  
Anaplastic Lymphoma Kinase Inhibitor ◽  
Anaplastic Lymphoma

Abstract Ovarian cancer is prone to recurrence and chemotherapy resistance. Ovarian tumours of some patients have been positive for anaplastic lymphoma kinase fusion gene expression (ALK+). Preclinical studies indicate that anaplastic lymphoma kinase inhibitor can suppress the growth of ovarian cancer cells and transplantation tumours. Here, we present a patient with metastatic ALK+ high-grade serous ovarian cancer that testing positive for EML4-ALK (microtubule-associated protein-like 4 gene, fused to the anaplastic lymphoma kinase gene), experienced dramatic benefit after administration of the anaplastic lymphoma kinase inhibitor alectinib. This is the first clinical evidence that treatment with alectinib may provide a personalized maximum benefit for patients with high-grade serous ovarian cancer who are positive for EML4-ALK.

scholarly journals Ceritinib: A primer for pharmacists

2016 ◽  
Vol 23 (8) ◽  
pp. 602-614 ◽  
Author(s):  
Trang H Au ◽  
Courtney C Cavalieri ◽  
David D Stenehjem
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Anaplastic Lymphoma Kinase ◽  
Kinase Inhibitor ◽  
Small Cell ◽  
Small Cell Lung ◽  
Clinical Pharmacists ◽  
Anaplastic Lymphoma Kinase Inhibitor ◽  
Anaplastic Lymphoma

Clinical pharmacists are important contributors to the care of patients with cancer; it is therefore critical for oncology clinical pharmacists to stay current with new anticancer therapies. This review summarizes the epidemiology and pathogenesis of non-small cell lung cancer, including the most common genetic alterations, as well as the mechanism of action, clinical development, pharmacodynamics and pharmacokinetics of the anaplastic lymphoma kinase inhibitor ceritinib for the treatment of patients with anaplastic lymphoma kinase-positive non-small cell lung cancer. Targeted therapies based on the presence of specific mutations are an important development in the treatment of non-small cell lung cancer. However, acquired resistance to the first anaplastic lymphoma kinase-inhibitor approved by the U.S. Food and Drug Administration, crizotinib, is observed in almost half of patients treated with it. Ceritinib is an oral anaplastic lymphoma kinase-inhibitor that has demonstrated more potent antitumor activity than crizotinib in preclinical models. It was granted accelerated approval in 2014 to treat anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer patients who have progressed on or are intolerant to crizotinib. Ceritinib represents an important alternative second-line therapy for patients with metastatic non-small cell lung cancer who have traditionally limited treatment options.

scholarly journals Insight on Mutation-Induced Resistance from Molecular Dynamics Simulations of the Native and Mutated CSF-1R and KIT

PLoS ONE ◽  
2016 ◽  
Vol 11 (7) ◽  
pp. e0160165 ◽  
Author(s):  
Priscila Da Silva Figueiredo Celestino Gomes ◽  
Isaure Chauvot De Beauchêne ◽  
Nicolas Panel ◽  
Sophie Lopez ◽  
Paulo De Sepulveda ◽  
...  
Keyword(s):  
Molecular Dynamics ◽  
Molecular Dynamics Simulations ◽  
Induced Resistance ◽  
Dynamics Simulations

Crizotinib: an anaplastic lymphoma kinase inhibitor

2011 ◽  
Vol 7 (8) ◽  
pp. 947-953 ◽  
Author(s):  
Shirish M Gadgeel ◽  
Gerold Bepler
Keyword(s):  
Anaplastic Lymphoma Kinase ◽  
Kinase Inhibitor ◽  
Anaplastic Lymphoma Kinase Inhibitor ◽  
Anaplastic Lymphoma

New-Generation Anaplastic Lymphoma Kinase Inhibitor Experience in a Case With Non–Small Cell Lung Cancer

2020 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Mahmut Buyuksimsek ◽  
Semra Paydas ◽  
Abdullah Evren Yetisir ◽  
Cem Mirili ◽  
Ali Ogul ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Anaplastic Lymphoma Kinase ◽  
Kinase Inhibitor ◽  
Small Cell ◽  
Small Cell Lung ◽  
Anaplastic Lymphoma Kinase Inhibitor ◽  
Anaplastic Lymphoma ◽  
New Generation
Sign in / Sign up

Export Citation Format

Share Document